课题基金 / 基金详情

ACTG388 EFAVIRENZ OR NELFINAVIR IN COMBINATION W/ FIXED DOSE COMBINAT

ACTG388 EFAVIRENZ OR NELFINAVIR IN COMBINATION W/ FIXED DOSE COMBINAT
ACTG388 依非韦伦或奈非那韦与固定剂量组合的组合
批准号：
6264877
负责人：
GILDON N BEALL
金额：
$0.1万
依托单位：
LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6264877
关键词：
AIDS therapy HIV infections antiAIDS agent clinical research combination chemotherapy drug adverse effect drug screening /evaluation human subject lamivudine protease inhibitor reverse transcriptase inhibitors zidovudine

项目摘要

项目成果

GILDON N BEALL的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
To evaluate strategies for treatment of HIV infection. The availability of a number of drugs that act against the virus together with the high cost and import-ant side effects of the drugs makes it necessary to study the best means for their use. The drug regimens to be used in the first phase are: FDC 3TC/ZDV+IDV; the same 3 drugs plus nelfinavir; the same three drugs plus efavirenz.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
ACTG 328--RECOMBINANT HUMAN IL 2 BY IV OR SC IN HIV PATIENTS ON HAART
ACTG388 EFAVIRENZ OR NELFINAVIR IN COMBINATION W/ FIXED DOSE COMBINAT
PHYSIOLOGIC TESTOSTERONE REPLACEMENT IN HIV INFECTED WOMEN
PHASE I/II DOSING SAFETY AND ANTIVIRAL ACTIVITY OF HYDROSYUREA ALONE/COMBINED
海外基金